Cancer diagnostics
Jun 30, 2022
LumiThera’s US LIGHTSITE III Trial; First Patient Enrolled in Vascular Closure Device Study of Teleflex; Varian’s Flash Technology Clinical Trial, FAST-02; 3Spine’s MOTUS Device; Illumina’s Research Test to Detect Tumor Genome; Acutus Medical’s AcQCross Qx System
LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) t...
Read More...
Mar 07, 2022
Top Five Liquid Biopsy Companies Impacting Cancer Diagnostics Market from 2020 to 2028
Cancer diagnostics is an umbrella term that encompasses all diagnostics modalities such as imaging, molecular diagnostics, and biopsy employed in drawing conclusions regarding cancer diagnosis and devising prognostic strategies. Liquid Biopsy is comparatively a new technique in the cancer diagnosis and the...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
